A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: Rationale, design and methods of Japan clinical oncology group study JCOG1314 (MIRACLE study)

Japan Clinical Oncology Group, Japan Esophageal Oncology Group

研究成果: Article

8 引用 (Scopus)

抜粋

Chemotherapy with cisplatin plus fluorouracil is the current standard treatment for metastatic or recurrent esophageal cancer.We have developed a 2-weekly docetaxel combined with CF regimen and conducted a Phase I/II trial for metastatic or recurrent esophageal cancer (JCOG0807). Promising efficacy and safety were shown in JCOG0807, and we have commenced a Phase III trial in September 2014 to confirm the superiority of 2-weekly DCF to CF for patients with metastatic or recurrent esophageal cancer. A total of 240 patients will be accrued from41 Japanese institutions over a period of 4 years. The primary end point is overall survival. The secondary end points are progression-free survival, response rate and proportion of adverse events.

元の言語English
ページ(範囲)494-498
ページ数5
ジャーナルJapanese journal of clinical oncology
45
発行部数5
DOI
出版物ステータスPublished - 2015 5 1

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

フィンガープリント A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: Rationale, design and methods of Japan clinical oncology group study JCOG1314 (MIRACLE study)' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用